Literature DB >> 21479622

Immunobiology of hepatocellular carcinoma.

Tobias Flecken1, Hans Christian Spangenberg, Robert Thimme.   

Abstract

INTRODUCTION: Hepatocellular carcinoma (HCC) is a tumor of increasing incidence and high mortality worldwide. Diagnosis of HCC is often difficult, especially at early stages of disease. Additionally, current treatment options are limited. HCC usually develops in an environment of chronic liver disease. The immune system has an important role in shaping this environment, especially in chronic viral hepatitis, the leading cause of HCC. However, the immune system also plays a role in natural immunity against HCC although this is apparently not sufficient to control the majority of tumors. This failure in tumor control is due to multiple immunomodulatory mechanisms employed by HCC to subvert the immune system. In this review, we will summarize the current knowledge about the role of the immune system in hepatocarcinogenesis. Additionally, we will describe the mechanisms used by the immune system to control established lesions and the reasons why these immune responses apparently fail so often. Finally, possible implications for the design of novel immunotherapeutic strategies will be discussed.

Entities:  

Mesh:

Year:  2011        PMID: 21479622     DOI: 10.1007/s00423-011-0783-x

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  82 in total

1.  Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection.

Authors:  H Huang; H Fujii; A Sankila; B M Mahler-Araujo; M Matsuda; G Cathomas; H Ohgaki
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

3.  Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients.

Authors:  Dong-Ming Kuang; Chen Peng; Qiyi Zhao; Yan Wu; Ling-Yan Zhu; Jianen Wang; Xiao-Yu Yin; Lian Li; Limin Zheng
Journal:  J Immunol       Date:  2010-06-25       Impact factor: 5.422

4.  Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion.

Authors:  W L Chuang; H W Liu; W Y Chang
Journal:  Cancer       Date:  1990-02-15       Impact factor: 6.860

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

Authors:  Noritoshi Kobayashi; Nobuyoshi Hiraoka; Wataru Yamagami; Hidenori Ojima; Yae Kanai; Tomoo Kosuge; Atsushi Nakajima; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

Review 8.  HCV-related hepatocellular carcinoma: From chronic inflammation to cancer.

Authors:  Giuseppe Castello; Stefania Scala; Giuseppe Palmieri; Steven A Curley; Francesco Izzo
Journal:  Clin Immunol       Date:  2009-11-11       Impact factor: 3.969

9.  A lymphotoxin-driven pathway to hepatocellular carcinoma.

Authors:  Johannes Haybaeck; Nicolas Zeller; Monika Julia Wolf; Achim Weber; Ulrich Wagner; Michael Odo Kurrer; Juliane Bremer; Giandomenica Iezzi; Rolf Graf; Pierre-Alain Clavien; Robert Thimme; Hubert Blum; Sergei A Nedospasov; Kurt Zatloukal; Muhammad Ramzan; Sandra Ciesek; Thomas Pietschmann; Patrice N Marche; Michael Karin; Manfred Kopf; Jeffrey L Browning; Adriano Aguzzi; Mathias Heikenwalder
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

10.  CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver.

Authors:  Takuya Miyagi; Tetsuo Takehara; Tomohide Tatsumi; Tatsuya Kanto; Takahiro Suzuki; Masahisa Jinushi; Yoshiko Sugimoto; Yutaka Sasaki; Masatsugu Hori; Norio Hayashi
Journal:  Int J Cancer       Date:  2003-08-10       Impact factor: 7.396

View more
  10 in total

1.  Immunomodulatory Magnetic Microspheres for Augmenting Tumor-Specific Infiltration of Natural Killer (NK) Cells.

Authors:  Wooram Park; Andrew C Gordon; Soojeong Cho; Xiaoke Huang; Kathleen R Harris; Andrew C Larson; Dong-Hyun Kim
Journal:  ACS Appl Mater Interfaces       Date:  2017-04-17       Impact factor: 9.229

2.  Guardian and selective killer: the versatile functions of TLR3 in hepatocellular carcinoma.

Authors:  Chen Liu
Journal:  J Natl Cancer Inst       Date:  2012-11-29       Impact factor: 13.506

3.  A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.

Authors:  Dan-Dan Xiong; Yue Qin; Wen-Qing Xu; Rong-Quan He; Hua-Yu Wu; Dan-Min Wei; Jing-Jing Zeng; Yi-Wu Dang; Gang Chen
Journal:  Clin Drug Investig       Date:  2018-10       Impact factor: 2.859

Review 4.  Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.

Authors:  Yu-Peng Hong; Zi-Duo Li; Pankaj Prasoon; Qi Zhang
Journal:  World J Hepatol       Date:  2015-05-08

5.  Low Frequency of Peripheral Lymphocyte in Chronic Hepatitis B Patients Predicts Poor Progression to Hepatocellular Carcinoma.

Authors:  Jian Li; Juan Li; Yunwen Bao; Kunyi Pan; Xianghua Lin; Xiaoqiang Liu; Han Wang; Ying Xu; Xiaohong Luo; Hongyu Li; Chaohui Duan
Journal:  J Clin Lab Anal       Date:  2015-01-19       Impact factor: 2.352

Review 6.  Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer.

Authors:  Jessica Brownell; Stephen J Polyak
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

7.  CD24 promotes HCC progression via triggering Notch-related EMT and modulation of tumor microenvironment.

Authors:  Xin Wan; Ci Cheng; Qing Shao; Zhe Lin; Shuai Lu; Yun Chen
Journal:  Tumour Biol       Date:  2015-11-25

8.  Identification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma.

Authors:  Xiaofeng Li; Jirun Peng; Yanli Pang; Sen Yu; Xin Yu; Pengcheng Chen; Wenzhen Wang; Wenling Han; Jun Zhang; Yanhui Yin; Yu Zhang
Journal:  Sci Rep       Date:  2015-10-06       Impact factor: 4.379

9.  The Landscape of Early Growth Response Family Members 1-4 in Hepatocellular Carcinoma: Their Biological Roles and Diagnostic Utility.

Authors:  Jinlong Liang; Jingyi Wang; Jinshui Zeng; Zhibo Bai; Zhiyuan Zheng; Yue Zheng; Fengqi Jiang; Di Wu
Journal:  Dis Markers       Date:  2022-08-22       Impact factor: 3.464

10.  Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker.

Authors:  Aileen Marshall; Margus Lukk; Claudia Kutter; Susan Davies; Graeme Alexander; Duncan T Odom
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.